Finnish AI device brings continuous brain monitoring to intensive care

A Finnish medical technology company has developed an AI-powered device that enables continuous monitoring of brain activity in intensive care patients, addressing a long-standing gap in critical care where brain function has often gone unmonitored compared to heart and lung activity.

The Oulu-based firm Cerenion’s system uses artificial intelligence to interpret complex electroencephalogram (EEG) data, converting it into easily understandable information for medical staff, according to a report by Finnish public broadcaster Yle. The technology is already in use in several major hospitals across Finland, where brain activity was previously tracked only intermittently.

Tero Ala-Kokko, chief physician of the intensive care unit at Oulu University Hospital (OYS), noted that brain function has historically been monitored far less systematically than other vital organs, despite its critical role in patient outcomes. “Brain activity is currently monitored far less frequently and less systematically than heart or lung function, even though it is central to the patient’s prognosis,” he said.

The device was conceived by Jukka Kortelainen, a physician and engineer, who identified the problem over a decade ago while researching cardiac arrest patients. He observed that EEG patterns could provide early indicators of recovery, sparking both medical and commercial interest. “In my view, only through commercialization can such a research finding be brought into practical use,” Kortelainen told Yle.

Traditional EEG monitoring has faced two major obstacles: the need for specialized equipment and trained personnel, causing delays, and the requirement for expert interpretation, typically by neurologists or clinical neurophysiologists—specialists not always available, particularly during off-hours. Cerenion’s solution simplifies the process with a user-friendly sensor placed on the forehead, eliminating the need for extensive training. The AI then processes the raw EEG data into clear numerical values, allowing non-specialist staff to assess a patient’s condition.

The system’s potential extends beyond routine monitoring. Ala-Kokko highlighted its ability to detect non-convulsive epileptic seizures, which often go unnoticed in standard care. “The device’s greatest strength is that it makes brain activity visible in a way that integrates better into daily intensive care routines,” he said.

Cerenion recently secured over €4.3 million in funding from Finnish private investors and family offices, which will accelerate its international expansion. The company estimates the annual market potential for its technology at approximately €1 billion each in Europe and Asia, with a global market nearing €5 billion. The device has obtained CE marking, clearing the way for sales in the EU and key Asian markets.

At Oulu University Hospital, the BrainStatus monitor—equipped with Cerenion’s software—is used for prognostic evaluations in cardiac arrest patients and epilepsy diagnostics. Staff report the system is technically straightforward to deploy without extensive training, though final diagnostic interpretation remains the responsibility of neurologists.